Website maintenance:

We will carry out maintenance on the website for a period to come. We apologize in advance for any problems this may cause. If you are unable to access the website it is probably due to updates. Please try to re-enter the website in 10 minutes time. Sincerely, The Web Development team!

New treatment for hereditary ovarian cancer approved in Norway

Photo: Kent Skibstad / NTB scanpix

Advertisement

On Thursday, a new cancer treatment was approved for patients in Norway for a limited time. Experts call it personalized medicine at its very best.

According to VG, the new treatment, the drug Lynparza (olaparib), has shown a 70 percent lower risk of relapse or death in a test group than in those receiving placebo. The cancer treatment is approved in Europe and the US and was approved on Thursday in Norway for a limited time.

This is the biggest breakthrough in gynecological cancer in many years and the largest that has occurred in cancer treatment since immunotherapy. There is great potential for a cure, says Professor Line Bjørge at the University of Bergen.

The treatment is aimed at patients with the inherited gene defect BRCA mutation, with a high risk of developing ovarian cancer and cancer at a younger age. These patients have an average age of 52 years.

According to calculations, the medicine should be relevant for 30-40 patients in Norway. Bjørge says there is hope that long-term survival for the patient group can be increased from the current 20 percent to 50 percent.

© NTB Scanpix / #Norway Today

RSS Feed

Advertisement